- RecruitingPHASE3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This study compares two treatments for multiple myeloma that has come back or not responded to previous treatments. It looks at a new drug, mezigdomide, combined with standard medicines (bortezomib and dexamethasone), against another combination (pomalidomide, bortezomib, and dexamethasone). The aim is to see which combination is more effective and safe.
For: Relapsed or Refractory Multiple MyelomaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
This study is looking into a new combination of medicines for people in the UK with multiple myeloma that has come back or not responded to previous treatments. It compares a new medicine combination with a standard one to see if the new option works better.
For: Relapsed or Refractory Multiple MyelomaUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
This study is testing a new drug called Etentamig for adults with multiple myeloma, a type of blood cancer. Researchers want to see if it's safe and effective when given alone or with other common treatments to help manage the disease.
For: Multiple MyelomaUnited States · Australia · Israel - RecruitingPHASE1, PHASE2
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
This study is for people in the UK with multiple myeloma that has come back or not responded to previous treatments. It's testing a new combination of medicines, mezigdomide and elranatamab, to see if they are safe, what dose works best, and how well they might treat the cancer.
For: Multiple MyelomaUnited States · Canada · China